TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

FILSUVEZ

BIRCH TRITERPENES
Dermatology Approved 2023-12-18
1
Indication
--
Phase 3 Trials
1
Priority Reviews
2
Years on Market

Details

Status
Prescription
First Approved
2023-12-18
Routes
TOPICAL
Dosage Forms
GEL

Companies

Active Ingredient: BIRCH TRITERPENES

FILSUVEZ Approval History

Loading approval history...

What FILSUVEZ Treats

1 indications

FILSUVEZ is approved for 1 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Epidermolysis Bullosa
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FILSUVEZ FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older. FILSUVEZ topical gel is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6 months of age and older.

FILSUVEZ Patents & Exclusivity

Latest Patent: Jan 2039
Exclusivity: Dec 2030

Patents (6 active)

US11266660 Expires Jan 4, 2039
US12268695 Expires Jan 4, 2039
US11083733 Expires Jan 4, 2039
US9827214 Expires Nov 24, 2030
US9352041 Expires Nov 24, 2030
US8828444 Expires Jun 21, 2026

Exclusivity

NCE Until Dec 2028
ODE-460 Until Dec 2030
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.